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 Our goals in this grant application are directed towards the development of radiotracers that may allow 
the study of the high-affinity state (functional state) of the dopamine receptors.  There have been numerous 
reports on the presence of two inter-convertible states of these (G-protein coupled) receptors in vitro.  
However, there is no report that establishes the presence of these separate affinity states in vivo.  We have 
made efforts in this direction in order to provide such direct in vivo evidence about the presence of the high 
affinity state.  This understanding of the functional state of the receptors is of critical significance in our 
overall diagnosis and treatment of diseases that implicate the G-protein coupled receptors.  Four specific 
aims have been listed in the grant application: (1).  Design and syntheses of agonists  (2).  Radiosyntheses of 
agonists  (3).  In vitro pharmacology of agonists  (4).  In vivo distribution and pharmacology of labeled 
derivatives.  We have accomplished the syntheses and radiosyntheses of three agonist radiotracers labeled 
with carbon-11.  In vitro and in vivo pharmacological experiments have been accomplished in rats and 
preliminary PET studies in non-human primates have been carried out.  Various accomplishments during the 
funded years, briefly outlined in this document, have been disseminated by several publications in various 
journals and presentations in national and international meetings (Society of Nuclear Medicine, Society for 
Neuroscience and International Symposium on Radiopharmaceutical Chemistry). 
 
1.  Design and Syntheses of Agonists. 
 
 Our basic approach towards the development of tracers that may allow the study of high affinity states 
arises from the following facts:  Critical amino acid residues in the D-2 receptor serve two principal 
purposes: 1) bind dopamine and 2) trigger a response subsequent to binding of dopamine.  Structural 
requirements of dopamine in order to attain the two separate goals are distinct but have some overlap.  Our 
approach has been two-fold: One is the development of “high affinity agonists”, such as ZYY-339 and its 
analogs; and second is the development of “silent agonists”. 
 
Silent Agonists 
 A number of agonists for the dopamine D-2 receptor have been reported.  A significant amount of 
evidence has accumulated using dopamine D-2 receptor agonists which show the importance of interaction 
of the nitrogen as well as the hydroxyl groups.  Extensive site-directed mutagenesis studies in adrenergic 
receptors have inferred similar findings on the importance of the nitrogen in binding to the receptor active 
site and the role of the catecholic hydroxyl groups in interacting with the serine residues (Mansour et al., 
1990; Cox et al., 1992).  Interaction of the hydroxyl groups with the serine residues results in signal 
transduction via coupling to G-proteins. 
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Figure-1.   Chemical structures of silent agonists. 
 
 We had postulated that by removing the hydroxyl group and substituting it with a hydrogen, chlorine etc 
(Figure-1) would provide “silent agonists” with slower dissociation rate constants.  This would then make 
the development of imaging agents based on agonists somewhat easier.  However, our binding affinity data 
and some reported data indicates the necessity of the hydroxyl group at the 5-position in order to maintain 
high affinity for the D-2 receptors.  It may be inferred from this preliminary data that the hydroxyl group 
may play a more significant role at the 5-position.  Thus in summary, silent agonists without the 5-hydroxyl 
group exhibit low affinity and may not thus be able to serve as good PET imaging agents. 
 
High Affinity Agonists 
 Using structure-activity information on the various agonists for dopamine receptors, such as 2-(N-
phenethyl-N-propyl)-amino-5-hydroxytetralin (PPHT), we have synthesized high affinity agonists which 
may be developed as potential in vivo radiotracers in order to exclusively study the high-affinity state.  We 
have prepared various analogs of PPHT which contain a alkyl, substituted aryl and cyclohexyl group instead 
of a phenyl group.  Incorporation of the cyclohexyl group as in 2-(N-cyclohexylethyl-N-propyl)amino-5-
hydroxytetralin (ZYY-339) significantly enhances the affinity of these compounds.  In order to radiolabel the 
agonists with carbon-11, three compounds which differed in their affinities for the D-2 receptor were chosen 
for in vivo studies (Figure-2). 
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______________________________________________________________________________ 
Compound   R         Affinity (nM) a   Log P b 
______________________________________________________________________________ 
1.     CH3CH2CH2 (5OH-DPAT)   2.5±0.40     1.37±0.03 
2.     C6H5CH2CH2 (PPHT)    0.65±0.10     3.034±0.003   
3.     C6H11CH2CH2  (ZYY-339)   0.01±0.005    3.089±0.006 
______________________________________________________________________________ 
a Affinity, IC50 values using 3H-spiperone; b Log P were measured by partitioning the compounds  
between n-octanol and phosphate buffer at pH 7.4. 
 
Figure-2:  In Vitro Affinities and Lipophilicity of Selected Agonists 
 
2.  Radiosyntheses of agonists. 
 In order to evaluate the ability of the high affinity agonists in vivo, we carried out carbon-11 
radiosynthesis of three derivatives (a general reaction scheme is shown for 11C-ZYY-339 in Figure-3).  
Radiosynthesis of 2-(N-cyclohexylethyl-N-1’-11C-propyl)amino-5-hydroxytetralin (11C-ZYY-339), 2-(N-
phenethyl-N-1’-11C-propyl)amino-5-hydroxytetralin (11C-PPHT) and 2-(N-propyl-N-1’-11C-propyl)amino-5-
hydroxytetralin (11C-5OH-DPAT) has been carried out. Radiosynthesis of 11C-propionyl chloride and 
subsequent coupling to form an amide of the respective precursors followed by reduction provides the 
radiotracers in 5 to 10% radiochemical yield in specific activities of 500 to 1000 Ci/mmol after reverse-
phase HPLC purification. 
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Figure-3:  General Scheme for Carbon-11 Radiolabeling of the Agonists 
 
 In vitro autoradiographic studies have been completed with all the three carbon-11 derivatives and a 
manuscript describing the radiosyntheses and in vitro autoradiographic data has been published (Shi et al., 
1999). 
 
3.  In vitro pharmacology of agonists. 
 In 3H-spiperone assays using rat striata, ZYY-339 exhibited subnanomolar affinity for D-2 receptor high-
affinity sites (IC50 = 0.010 nM), while 2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin (PPHT) and 2-(N, 
N-dipropyl)amino-5-hydroxytetralin (5OH-DPAT) exhibited an affinity of 0.65 nM and 2.5 nM, 
respectively.  Removal of the phenolic hydroxyl however, decreased the affinity dramatically. We also 
analyzed the effect of 5’-guanylylimidodiphosphate (Gpp(NH)p, 150 microM), the non-hydrolysable GTP 
analog on ZYY-339 using 3H-spiperone assays.   Binding of ZYY-339 was reduced by more than an order of 
magnitude at the high affinity site, indicative of an agonist behavior.  Further pharmacological studies of 
other derivatives (agonists and silent agonists) are in progress and a manuscript describing these findings is 
under preparation (Yang et al., 1999). 
 
  11C-5-OH-DPAT       11C-PPHT            11C-ZYY-339 
       
 
 Figure-4 In Vitro Rat Brain Sections showing binding of 11C-DPAT, 11C-PPHT and 
11C-ZYY-339 
 
 Coronal tissue sections (20 µm) were placed in 50 mM Tris HCl buffer (pH 7.4, 25 oC) containing 120 
mM NaCl and 5 mM KCl and were preincubated for 15 minutes. The slices were then incubated with 11C-5-
OH-DPAT, 11C-PPHT and 11C-ZYY-339 at concentrations of approx. 0.1 to 1 nM) for 30 minutes at 25 oC.  
Non-specific binding was defined as the binding remaining in the presence of 10 µM (S)-sulpiride.  
Following incubation, tissue sections were briefly washed twice for 0.5 min period each with cold 50 mM 
Tris HCl buffer, pH 7.4, followed by a quick rinse in cold deionised water.  The slices were apposed to 
phosphor screens and read by the Cyclone (Figure-4). 
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  11C-5-OH-DPAT       11C-PPHT            11C-ZYY-339 
            
 
Figure-5. In Vitro Rat Brain Sections Showing Effects of Gpp(NH)p on the Binding of 11C-
DPAT, 11C-PPHT and 11C-ZYY-339 
 
 In the case of experiments with 5’-guanylylimidophosphate (Gpp(NH)p), which is known to convert the 
HA-affinity sites to LA-affinity sites (Nobrega and Seeman, 1994), brain slices were preincubated for  15 
mins at 25 oC with the above mentioned buffer containing 150 µM of (Gpp(NH)p).  The slices were 
incubated with 11C-5-OH-DPAT, 11C-PPHT and 11C-ZYY-339  at concentrations of approx. 0.1 to 1 nM) for 
30 minutes at 25 oC.  Non-specific binding was defined as the binding remaining in the presence of 10 µM 
(S)-sulpiride.  Specific binding with all the three radiotracers was significantly reduced suggestive of high-
affinity state binding (Figure-5). 
 
4.  In vivo distribution and pharmacology of labeled derivatives. 
 
 In vivo studies with the radiotracers were carried out by intracardiac administration of the respective 
radiotracers in groups of Sprague-Dawley rats (controls, prereserpinized with 5 mg/kg and haloperidol, 1 
mg/kg, pretreated).  Male Sprague-Dawley rats (approx. 200 g) were administered 100 µCi of 11C-5-OH-
DPAT by intracardiac injection in a volume of 200 µl.  A group of rats were prereserpinized (5 mg/kg, ip) 24 
hrs prior to the experiment.  Haldol (1 mg/kg) was injected 15 min. prior to the injection of the  radiotracer.   
Animals were sacrificed at 15 mins pi.  Figure-6 shows the selective binding in the striata which was reduced 
in the presence of haloperidol.  It must be noted that all these experiments are with the racemic mixture and 
thus a significant amount of non-specific binding may be attributed to the less-active isomer. 
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Figure-6. 11C-5-OH-DPAT in Rat Brain Regions 
 
 Both 11C-ZYY-339 and 11C-PPHT indicated preferential localization in the striata compared to 
cerebellum (S/C = 1.94 and 1.22 respectively; Figure-7).  Pretreatment with reserpine improved the binding 
in the striata for both radiotracers as seen in the striata/cerebellum ratios (2.17 and 1.44, respectively), 
whereas haldol reduced this selective binding.  A high degree of cortical binding was observed with both the 
radiotracers.  Improvements of specific activities are also underway in order to improve the extent of specific 
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binding.  Further experiments are underway in order to demonstrate the nature of this binding i.e., to the high 
and/or low affinity state of the D-2 receptor using autoradiographic methods. 
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Figure-7. PET Time-Activity Curve of 11C-PPHT and 11C-ZYY-339 
in Rat Brain Regions 
 
5.  PET Studies of labeled derivatives in Monkeys. 
 
 Rhesus monkeys were used to carry out PET studies with the agonists.  The head of the animal was 
placed in the gantry of a Siemen’s CTI HR+ scanner and positioned in  place with the use of adhesive tape.  
Image slices of the whole brain parallel to the canthomeatal plane were acquired in 3-D mode.  A 2.4 mm 
thick brain slice from a PET study of a rhesus monkey post-injection of 11C-5-OH-DPAT (3.43 mCi).  
Localization of 11C-5-OH-DPAT in the striata is seen  clearly, while some cortical binding is also seen 
(Figure-8).  The image is a sum of dynamic frames from 11 to 57 minutes. 
 
 
 
 
Figure-8. PET Time-Activity Curve of 11C-5-OH-DPAT in Monkey Brain Regions 
 
 
 Image slices of the whole brain parallel to the canthomeatal plane were acquired in 3-D mode.  A 2.4 mm 
thick brain slice from a PET study of a rhesus monkey post-injection of 11C-PPHT (2.5 mCi).  Localization 
of 11C-PPHT in the striata is seen clearly, with a larger amount of cortical binding compared to that of 5-OH-
DPAT is seen (Figure-9).  The image is at 57 minutes. 
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Figure-9. PET Time-Activity Curve of 11C-PPHT in Monkey Brain Regions 
 
 Image slices of the whole brain parallel to the canthomeatal plane were acquired in 3-D mode.  A 2.4 mm 
thick brain slice from a PET study of a rhesus monkey post-injection of 11C-ZYY-339 (0.75 mCi).  
Localization of 11C-ZYY-339 in the striata is seen clearly, while a significant amount of cortical binding is 
also seen (Figure-10).   
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Figure-10. PET Time-Activity Curve of 11C-ZYY-339 in Monkey Brain Regions 
 
 Image slices of the whole brain parallel to the canthomeatal plane were acquired in 3-D mode.  A 2.4 mm 
thick brain slice from a PET study of a rhesus monkey post-injection of 11C-ZYY-339 (0.7 mCi).  
 Localization of 11C-ZYY-339 in the striata (red) is seen clearly, while some cortical binding is also seen 
 (yellow-green).  The image is a sum of dynamic frames from 42 to 57 minutes. 
 
Summary 
• We have prepared the high affinity dopamine D-2 receptor agonist derivatives ZYY-339 and its various 
analogs.  Guanine nucleotide analog, Gpp(NH)p reduces its affinity in vitro. 
• Attempts to develop analogs without the phenolic hydroxy group as potential PET radiotracers were not 
successful due to the marked reduction in the D-2 receptor affinity. 
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• Carbon-11 analogs, 11C-5-OH-DPAT, 11C-PPHT and 11C-ZYY-339 have been succesfully prepared in 
moderate radiochemical yields. 
• The three agonists, 11C-5-OH-DPAT, 11C-PPHT and 11C-ZYY-339 indicated preferential localization in 
the striata compared to the cerebellum.  Pretreatment with reserpine improved the binding in the striata 
for both radiotracers as seen in the striata/cerebellum ratio plots below, whereas haldol reduced this 
selective binding. 
• Autoradiographic experiments, in vitro,  indicate the binding of the three agonists to the high-affinity 
sites.  Efforts will be made to demonstrate the high-affinity state binding in vivo. 
• Preliminary PET studies with the three agonists indicate selective localization in the striata.  A striata to 
cerebellum ratio of approximately 2 was obtained in the case of the three radiotracers.  It must be noted 
that all experiments have been carried out with the racemic (R,S)- 11C-5-OH-DPAT.  It is known that the 
(S)-isomer of 5-OH-DPAT has higher affinity than the (R)-isomer (Malmberg et al., 1994).  It is 
therefore likely that the radiolabeling of the pure (S)-isomer of 5-OH-DPAT may result in a higher target 
to nontarget ratios.  Furthermore, due to the somewhat complex radiosynthetic procedures, specific 
activities of 11C-5-OH-DPAT are approximately 500 to 1000 Ci/mmol and are considered to be moderate 
(Shi et al., manuscript under review).  It is likely that improvements in specific activities will further 
improve the quality of the PET data.  Studies are currently underway in order to identify one of the 
agonists for further investigations. 
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